We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Corneal Thinning During Topical Bevacizumab Therapy

This study has been withdrawn prior to enrollment.
(Side effect can increase the risk of the research)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00515684
First Posted: August 14, 2007
Last Update Posted: May 1, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Yonsei University
  Purpose
The purpose of this study is to determine whether topical bevacizumab is safe or not when used in corneal neovascularization for long term period.

Condition Intervention
Corneal Neovascularization Drug: bevacizumab (Avastin)

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science

Resource links provided by NLM:


Further study details as provided by Yonsei University:

Enrollment: 0
Study Start Date: May 2007
Study Completion Date: December 2008
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • clinical diagnosis of corneal neovascularization
  • must be able to apply eyedrop

Exclusion Criteria:

  • have active keratitis
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00515684


Locations
Korea, Republic of
Severance hospital
Seoul, Korea, Republic of
Sponsors and Collaborators
Yonsei University
Investigators
Principal Investigator: Sang Woo Kim, M.D. Severance hospital, Seoul , Korea
  More Information

ClinicalTrials.gov Identifier: NCT00515684     History of Changes
Other Study ID Numbers: 4-2006-0234
First Submitted: August 13, 2007
First Posted: August 14, 2007
Last Update Posted: May 1, 2015
Last Verified: April 2015

Additional relevant MeSH terms:
Neovascularization, Pathologic
Corneal Neovascularization
Metaplasia
Pathologic Processes
Corneal Diseases
Eye Diseases
Bevacizumab
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents